Citius Pharmaceuticals, Inc.
CTXR
Positions held
Your positionsCTXR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $13.42M | Enterprise value | $12.88M | Trailing P/E | — | Forward P/E | -0.34 |
| PEG | — | Price / book | 0.20 | Beta | 1.00 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 77.3% | Operating margin | -6.7% |
| Profit margin | 0.0% | ROE | -81.1% | ROA | -26.6% | Debt / equity | 0.09 |
| Current ratio | 0.84 | Free cash flow | -$36.80M | Analyst recommendation | none | Mean target | $4.00 |
| 52w high | $2.19 | 52w low | $0.47 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $3.9M | $0.0M | $0.0M | — |
| Op margin | -670.2% | -1827.8% | -214.1% | — | — | — |
| Net income | -$8.9M | -$21.2M | -$8.2M | -$8.0M | -$8.8M | — |
| Gross margin | 67.1% | 80.3% | 80.0% | — | — | — |
| Gross profit | $1.0M | $1.3M | $3.2M | — | $0.0M | $0.0M |
| Operating income | -$10.0M | -$30.5M | -$8.4M | -$8.4M | -$8.8M | — |
- Revenue -10% vs prior quarter ($1.5M vs $1.7M).
- Gross margin 67.1% (was 80.3% prior quarter).
- Operating margin expanded to -670.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$37.4M | -$39.1M | -$32.5M | -$33.6M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$38.5M | -$42.0M | -$36.7M | -$33.3M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-03 · Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
2026-08-14 · Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
2026-08-14 · Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
2026-08-12 · Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
2026-08-05 · Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
Price (daily)
Full chart · RSI · MACD · patterns